All Trials

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) after progression on ADT receive AZD6621 monotherapy, a multispecific T‑cell–engaging antibody targeting STEAP2 on tumor cells and CD3/CD8 to preferentially activate CD8+ T cells; two administration routes are explored with dose escalation and expansion. Key exclusions include significant cardiac disease/QT prolongation, uncontrolled autoimmune disease, prior severe CRS/ICANS, active CNS disease, and recent cellular therapy.

ClinicalTrials.gov ID: NCT07192614

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) with documented progression and adequate organ function receive AZD0516, a STEAP2‑targeted antibody–drug conjugate delivering an exatecan topoisomerase I inhibitor, either as monotherapy or combined with AZD9574 (palacaparib), a selective PARP1 inhibitor. Requires available tumor tissue; excludes prior STEAP2‑targeted therapy and significant CNS, pulmonary, infectious, or cardiovascular comorbidities.

ClinicalTrials.gov ID: NCT07181161

Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adult men with metastatic castration-resistant prostate cancer after at least one AR pathway inhibitor, ECOG 0–1, receive oral KTX-2001 (first-in-class NSD2 histone methyltransferase inhibitor targeting H3K36me2) as monotherapy or combined with darolutamide 600 mg BID. Excludes unstable CNS disease and significant cardiac/infection risks; aims to establish safety, PK/PD, and preliminary activity to define MTD/RP2D.

ClinicalTrials.gov ID: NCT07103018

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with DLL3-expressing advanced solid tumors, including previously treated SCLC or LCNEC (dose escalation) and expansion cohorts of SCLC (≤2 prior lines), de novo or treatment-emergent NEPC, and GEP-NEC; some cohorts require demonstrable uptake on 111In-ETN029 SPECT. Single-arm therapy with 225Ac-ETN029, a DLL3-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to tumor cells, with optional 111In-ETN029 imaging/dosimetry.

ClinicalTrials.gov ID: NCT07006727

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adolescents and adults (≥12) with advanced/metastatic soft tissue or bone sarcoma after ≥1 prior systemic therapy (ECOG 0–1); dose‑expansion focuses on unresectable recurrent/metastatic osteosarcoma. Treatment is cyclophosphamide lymphodepletion followed by a single infusion of autologous T cells engineered to display tumor‑targeted, membrane‑anchored IL‑12 that binds cell‑surface vimentin to localize IL‑12 activity and boost intratumoral IFN‑γ–mediated immunity.

ClinicalTrials.gov ID: NCT05621668

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage SCLC that has progressed after ≥1 prior systemic therapy, including those with controlled brain metastases, receive tarlatamab (DLL3-directed bispecific T‑cell engager) combined with AB248 (CD8-targeted IL‑2 mutein fusion designed to selectively activate CD8+ T cells) to assess safety, dose, and preliminary efficacy. Excludes prior DLL3- or IL‑2/7/15–directed therapies and symptomatic CNS disease.

ClinicalTrials.gov ID: NCT07037758

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with peritoneal-only metastatic gastric or GEJ adenocarcinoma (ECOG 0–2) receive standard systemic chemotherapy followed by preoperative laparoscopic HIPEC, then gastrectomy with cytoreductive surgery and intraoperative HIPEC. Aims to improve progression-free and overall survival in patients without extra-peritoneal metastases.

ClinicalTrials.gov ID: NCT07178808

Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic urothelial carcinoma: refractory cohort includes patients progressing after platinum (if eligible) and prior PD-1/L1 therapy; first-line cohort includes treatment‑naive mUC (prior perioperative therapy allowed, prior IO >6 months). Treatments are enfortumab vedotin (anti–Nectin-4 ADC with MMAE) plus sacituzumab govitecan (anti–Trop-2 ADC with SN‑38) for refractory disease, and the same doublet plus pembrolizumab (anti–PD‑1) for first line.

ClinicalTrials.gov ID: NCT04724018

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.

ClinicalTrials.gov ID: NCT07182149

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates the safety and maximum tolerated dose of INBRX-106, a hexavalent OX40 agonist antibody, both alone and in combination with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors, including NSCLC, melanoma, and head and neck squamous cell carcinoma, who have progressed on standard therapies.

ClinicalTrials.gov ID: NCT04198766